Sign in

    Ram Selvaraju • H.C. Wainwright & Co.

    Ram Selvaraju's questions to Soleno Therapeutics Inc (SLNO) leadership

    Ram Selvaraju's questions to Soleno Therapeutics Inc (SLNO) leadership • Q1 2025

    Question

    On behalf of Ram Selvaraju, an analyst asked about the current competitive landscape for Prader-Willi syndrome hyperphagia and the perceived opportunity for Vykat XR outside the United States.

    Answer

    Executive Anish Bhatnagar identified Acadia's carbetocin and Aardvark's earlier-stage drug as the primary late-stage competitors. Executive James MacKaness characterized the ex-U.S. opportunity as 'very significant,' citing a consistent unmet need and patient prevalence, and noted that rare disease pricing in Europe is often favorable.

    Ask Fintool Equity Research AI

    Ram Selvaraju's questions to Axsome Therapeutics Inc (AXSM) leadership

    Ram Selvaraju's questions to Axsome Therapeutics Inc (AXSM) leadership • Q3 2024

    Question

    Eduardo, on for Ram Selvaraju of H.C. Wainwright, asked about the sales force plan for the fibromyalgia asset (AXS-14) and for color on the competitive landscape for binge eating disorder.

    Answer

    An executive, likely CCO Ari Maizel, explained the AXS-14 launch would be targeted, likely requiring a distinct sales force for specialists but leveraging the existing primary care team. CEO Herriot Tabuteau described the binge eating disorder market as large (7M patients) with significant unmet need, as there is only one approved product.

    Ask Fintool Equity Research AI